LEPONEX 100/MG 50/TAB

Indications

Off-Label Uses

Common off-label uses include refractory bipolar disorder/psychosis, Parkinson’s disease psychosis (typically at low doses), and severe refractory aggression/behavioral disturbance (including in dementia-use is high-risk and generally discouraged unless exceptional circumstances).

Dosage & Administration

Initial Dose

25mg once daily at bedtime on day 1 (or 12.5mg once daily if high risk for hypotension/sedation), then increase by 25-50mg/day as tolerated to 300-450mg/day by the end of 2-3 weeks.

Maintenance Dose

150-300mg/day in divided doses (usual maintenance range); some patients may require 300-450mg/day; maximum 900mg/day.

Maximum Dose

900mg daily.

Children's Dosage

Not approved for children. Off-label use in adolescents may start at 12.5mg once or twice daily, titrated slowly.

Dose Adjustment Notes

Titrate slowly to minimize orthostatic hypotension, sedation and seizure risk; if interrupted for >48 hours, restart at 12.5 mg once or twice daily and re-titrate. Reduce dose with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) and consider higher requirements in smokers; reduce dose when smoking stops. Use lower doses/cautious titration in hepatic/renal impairment and the elderly.

Safety & Warnings

Contraindications

Contraindications: hypersensitivity to clozapine; history of clozapine-induced agranulocytosis/severe neutropenia (or inability to comply with required ANC monitoring); myeloproliferative disorders; uncontrolled epilepsy; paralytic ileus; severe CNS depression/coma.

Warnings & Precautions

Warnings/precautions: mandatory ANC monitoring via a clozapine monitoring program with baseline ANC and scheduled follow-up; do not initiate if ANC below required threshold and interrupt/discontinue per ANC algorithms; slow titration to reduce hypotension/bradycardia/syncope and seizure risk; monitor for myocarditis/cardiomyopathy (especially early treatment) and discontinue if suspected; monitor metabolic parameters (weight, glucose, lipids); manage constipation proactively due to GI hypomotility risk; caution in cardiovascular disease, seizure history, hepatic/renal impairment and with interacting drugs/smoking changes.

Age Restriction

Pediatric use: safety and efficacy have not been established; use in patients <18 years is not routinely recommended and should be specialist-led if considered.

Drug Interactions

Interaction Severity

MAJOR/avoid: Carbamazepine (additive agranulocytosis/bone marrow suppression; generally contraindicated), strong CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin (markedly increase clozapine levels/toxicity), and caution with benzodiazepines especially during initiation (rare severe hypotension/respiratory depression). MODERATE: other CYP inhibitors/inducers affecting levels (e.g., some SSRIs), antihypertensives (additive hypotension), alcohol/other CNS depressants (additive sedation), lithium/other agents lowering seizure threshold (increased seizure/NMS-like risk).

Food Interaction

No clinically significant food restriction; may be taken with or without food.

Special Populations

Pregnancy

AU TGA: C; US FDA: Not assigned (Risk Summary: Neonates exposed to antipsychotics during the 3rd trimester are at risk for extrapyramidal symptoms and/or withdrawal symptoms; consult healthcare provider

Children

Not approved for children. Off-label use in adolescents may start at 12.5mg once or twice daily, titrated slowly.

Elderly

Start at lower doses (12.5mg once daily), titrate very slowly, monitor closely for orthostatic hypotension, sedation, and anticholinergic effects; not approved for dementia-related psychosis

Liver Impairment

Hepatic impairment: use with caution; start low and titrate slowly with LFT monitoring; consider dose reduction in significant impairment and discontinue if clinically significant hepatitis/jaundice occurs; avoid/use only with extreme caution in active or severe hepatic disease.

Storage & Patient Advice

Patient Counseling

Strict adherence to mandatory ANC/WBC monitoring is required before starting and throughout treatment; seek urgent care for infection symptoms (fever, sore throat, flu-like illness), chest pain, shortness of breath, palpitations/rapid heartbeat, or fainting. Do not stop clozapine abruptly; if doses are missed for >48 hours, contact the prescriber before restarting (re-titration is usually needed). Causes marked sedation and dizziness/orthostatic hypotension-avoid driving/operating machinery until effects are known; rise slowly. Avoid alcohol and other sedatives. Inform the prescriber/pharmacist about all medicines (including OTC/herbals) and any smoking changes (starting/stopping) because smoking induces CYP1A2 and can significantly change clozapine levels. Take with or without food. Prevent/treat constipation proactively (hydration, fiber, laxatives as advised) and monitor weight and glucose/lipids due to metabolic risk.

Monitoring Requirements

Mandatory ANC (and WBC where required) monitoring per local program/label: baseline ANC acceptable (commonly ≥1500/µL; ≥1000/µL in benign ethnic neutropenia where applicable), then frequent monitoring early in therapy with reduced frequency over time if stable. Also monitor weight/BMI, blood pressure/heart rate, fasting glucose/HbA1c and lipids, constipation/bowel function, and assess for myocarditis/cardiomyopathy (especially in the first weeks) and seizures; consider ECG and LFTs at baseline and periodically based on risk.

Pharmacology

Half-Life

Approximately 12 hours on average (commonly cited range ~6-26 hours; may be longer at steady state).

Bioavailability

Approximately 50-60% oral bioavailability (variable due to first-pass metabolism).

Metabolism

Extensive hepatic metabolism primarily via CYP1A2; CYP3A4 contributes, with minor roles for CYP2D6 (and others). Major metabolites include norclozapine (N-desmethylclozapine, active) and clozapine N-oxide.

Product Information

OTC Alternatives

No OTC alternative

Psych Class

Antipsychotic-Atypical

Controlled Substance

No

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.